{"title":"EXD2:线粒体翻译的新调控因子和癌症治疗的潜在靶点。","authors":"Travis H Stracker","doi":"10.1080/23723556.2018.1445943","DOIUrl":null,"url":null,"abstract":"<p><p>In recent work we identified Exonuclease 3'-5' domain-containing protein 2 (EXD2) as an RNase required for efficient mitochondrial translation. Here I describe in brief the cellular phenotypes caused by EXD2 deficiency and make the case that EXD2 inhibitors could be valuable agents for cancer therapy.</p>","PeriodicalId":520710,"journal":{"name":"Molecular & cellular oncology","volume":" ","pages":"e1445943"},"PeriodicalIF":0.0000,"publicationDate":"2018-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/23723556.2018.1445943","citationCount":"1","resultStr":"{\"title\":\"EXD2: A new regulator of mitochondrial translation and potential target for cancer therapy.\",\"authors\":\"Travis H Stracker\",\"doi\":\"10.1080/23723556.2018.1445943\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In recent work we identified Exonuclease 3'-5' domain-containing protein 2 (EXD2) as an RNase required for efficient mitochondrial translation. Here I describe in brief the cellular phenotypes caused by EXD2 deficiency and make the case that EXD2 inhibitors could be valuable agents for cancer therapy.</p>\",\"PeriodicalId\":520710,\"journal\":{\"name\":\"Molecular & cellular oncology\",\"volume\":\" \",\"pages\":\"e1445943\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-03-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/23723556.2018.1445943\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular & cellular oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/23723556.2018.1445943\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2018/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular & cellular oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/23723556.2018.1445943","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
EXD2: A new regulator of mitochondrial translation and potential target for cancer therapy.
In recent work we identified Exonuclease 3'-5' domain-containing protein 2 (EXD2) as an RNase required for efficient mitochondrial translation. Here I describe in brief the cellular phenotypes caused by EXD2 deficiency and make the case that EXD2 inhibitors could be valuable agents for cancer therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
